The New Alzheimer's Drug - Are We Closer to a Cure?: Caleb Alexander / Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health

50 million people worldwide have dementia, with 10 million new cases emerging annually. Alzheimer's disease is the most common form of dementia, but for 20-years, there have been no new drugs to tackle the disorder until now. In June, the US Food and Drug Administration approved Aducanumab, a new Alzheimer's medication. While this is a promising development, fierce debate surrounds its efficacy and approval process. FDA Advisory Committee member Dr. Alexander discusses this controversial drug.